Vishnu Garla, MD
Endocrinology, Diabetes & Metabolism · Jackson, MSNPI 1316175573
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Amgen at 35.2% of the total. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MS, where the typical reported total is $4,678.
Across 156 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novo Nordisk$354
- Pfizer$214
- Abbott$186
- Corcept Therapeutics$166
- Dexcom, Inc.$131
- plus $1K from 20 others
Across 269 payments — averaging $315.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$59K
- Novartis$19K
- Novo Nordisk$5K
- Merck$2K
What the payments were for
- Food & beverage$3,312100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 39 | $1,165 |
| Novo Nordisk | 20 | $354 |
| Pfizer | 12 | $214 |
| Abbott | 9 | $186 |
| Corcept Therapeutics | 8 | $166 |
| Dexcom, Inc. | 5 | $131 |
| Kyowa Kirin, Inc. | 5 | $118 |
| AbbVie | 8 | $118 |
| Lilly USA, LLC | 7 | $101 |
| Sanofi-aventis U.S. LLC | 5 | $100 |
| Recordati_rare_diseases_inc. | 4 | $80 |
| Bayer | 4 | $79 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| Medtronic | 4 | $61 |
| Radius Health, Inc. | 2 | $51 |
| GRT US Holding, Inc. | 3 | $50 |
| AstraZeneca | 4 | $48 |
| Ascendis Pharma Endocrinology Inc | 2 | $36 |
| Tandem Diabetes Care, Inc. | 2 | $36 |
| Ultragenyx Pharmaceutical Inc. | 2 | $34 |
| Shire North American Group Inc | 2 | $29 |
| BETA Bionics, Inc. | 2 | $21 |
| Boehringer Ingelheim | 1 | $18 |
| Merck | 1 | $18 |
| Nevro Corp. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,312 in reported general payments places this provider in the 35th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Signifor LarPasireotide Pamoate | 13 | $251,280 |
| ForteoTeriparatide | 12 | $49,552 |
| JardianceEmpagliflozin | 26 | $20,762 |
| TrulicityDulaglutide | 14 | $20,597 |
| OzempicSemaglutide | 15 | $19,379 |
| TradjentaLinagliptin | 29 | $14,835 |
| Novolog FlexpenInsulin Aspart | 49 | $9,853 |
| Desmopressin AcetateDesmopressin (Nonrefrigerated) | 11 | $9,348 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $7,097 |
| Cabergoline | 15 | $6,007 |
| Hydrocortisone | 121 | $5,384 |
| Testosterone | 28 | $5,021 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,598 |
| Humalog Kwikpen U-100Insulin Lispro | 18 | $3,152 |
| Levothyroxine Sodium | 204 | $2,017 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Recordati_rare_diseases_inc.Signifor Lar | $80 | $251,28013 claims |
| Lilly USA, LLCForteo, Trulicity | $101 | $70,14926 claims |
| Boehringer IngelheimJardiance, Tradjenta | $18 | $35,59755 claims |
| Novo NordiskOzempic | $354 | $19,37915 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $2,017204 claims |
| AbbVieSynthroid | $118 | $1,93822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Jackson
- Eric DyessJackson$885K
- Honey EastJackson$721K
- Ben SealeJackson$623K
- Amanda SchieferJackson$204K
- John SistrunkJackson$41K
- Raymond GrenfellJackson$16K
- Vanessa SandiferJackson$14K
- John KnightJackson$9K
- Jana PhillipsJackson$8K
- Robert EvansJackson$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.